Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 14.03% | -3.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.03% | -3.59% | |||
| Cost of Revenue | 22.96% | -3.96% | |||
| Gross Profit | 7.94% | -3.34% | |||
| SG&A Expenses | 13.24% | -6.39% | |||
| Depreciation & Amortization | 11.42% | 11.77% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.05% | -3.27% | |||
| Operating Income | -7.78% | -5.31% | |||
| Income Before Tax | 251.46% | -130.58% | |||
| Income Tax Expenses | 121.27% | -1,112.28% | |||
| Earnings from Continuing Operations | 566.36% | -94.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 566.36% | -94.38% | |||
| EBIT | -7.78% | -5.31% | |||
| EBITDA | -2.45% | -0.44% | |||
| EPS Basic | 560.00% | -94.38% | |||
| Normalized Basic EPS | -53.44% | -16.84% | |||
| EPS Diluted | 560.00% | -94.38% | |||
| Normalized Diluted EPS | -53.44% | -16.84% | |||
| Average Basic Shares Outstanding | 0.52% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.52% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||